

Neil O Carragher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/259081/publications.pdf>

Version: 2024-02-01

96
papers

7,116
citations

87888

38
h-index

60623

81
g-index

108
all docs

108
docs citations

108
times ranked

11353
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment. <i>Molecular Oncology</i> , 2022, 16, 1072-1090.	4.6	5
2	A Novel High-Content Phenotypic Screen To Identify Inhibitors of Mitochondrial DNA Maintenance in Trypanosomes. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0198021.	3.2	1
3	Chemical Interrogation of Nuclear Size Identifies Compounds with Cancer Cell Line-Specific Effects on Migration and Invasion. <i>ACS Chemical Biology</i> , 2022, 17, 680-700.	3.4	12
4	Multiparametric High-Content Cell Painting Identifies Copper Ionophores as Selective Modulators of Esophageal Cancer Phenotypes. <i>ACS Chemical Biology</i> , 2022, 17, 1876-1889.	3.4	11
5	Metastasis-associated macrophages constrain antitumor capability of natural killer cells in the metastatic site at least partially by membrane bound transforming growth factor β . , 2021, 9, e001740.		18
6	NODAL/TGF β 2 signalling mediates the self-sustained stemness induced by PIK3CAH1047R homozygosity in pluripotent stem cells. <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	2.4	5
7	High-content phenotypic and pathway profiling to advance drug discovery in diseases of unmet need. <i>Cell Chemical Biology</i> , 2021, 28, 338-355.	5.2	27
8	Automated <i>in vivo</i> drug screen in zebrafish identifies synapse-stabilising drugs with relevance to spinal muscular atrophy. <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	2.4	12
9	Application of a High-Content Screening Assay Utilizing Primary Human Lung Fibroblasts to Identify Antifibrotic Drugs for Rapid Repurposing in COVID-19 Patients. <i>SLAS Discovery</i> , 2021, 26, 1091-1106.	2.7	3
10	A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability. <i>Cancer Research</i> , 2021, 81, 5438-5450.	0.9	20
11	ISGylation drives basal breast tumour progression by promoting EGFR recycling and Akt signalling. <i>Oncogene</i> , 2021, 40, 6235-6247.	5.9	16
12	MISpherID: a knowledgebase and transparency tool for minimum information in spheroid identity. <i>Nature Methods</i> , 2021, 18, 1294-1303.	19.0	38
13	High content phenotypic screening identifies serotonin receptor modulators with selective activity upon breast cancer cell cycle and cytokine signaling pathways. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115209.	3.0	26
14	Brain microenvironment-driven resistance to immune and targeted therapies in acral melanoma. <i>ESMO Open</i> , 2020, 5, e000707.	4.5	3
15	Highly Conserved Homotrimer Cavity Formed by the SARS-CoV-2 Spike Glycoprotein: A Novel Binding Site. <i>Journal of Clinical Medicine</i> , 2020, 9, 1473.	2.4	73
16	High-Content Phenotypic Profiling in Esophageal Adenocarcinoma Identifies Selectively Active Pharmacological Classes of Drugs for Repurposing and Chemical Starting Points for Novel Drug Discovery. <i>SLAS Discovery</i> , 2020, 25, 770-782.	2.7	22
17	The retinal tyrosine kinome of diabetic Akimba mice highlights potential for specific Src family kinase inhibition in retinal vascular disease. <i>Experimental Eye Research</i> , 2020, 197, 108108.	2.6	8
18	Novel roles of PRK1 and PRK2 in cilia and cancer biology. <i>Scientific Reports</i> , 2020, 10, 3902.	3.3	10

#	ARTICLE	IF	CITATIONS
19	A Synergistic Anticancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemicalâ€“Genetic High-Content Phenotypic Screen. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 637-649.	4.1	16
20	Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma. <i>BMC Cancer</i> , 2020, 20, 269.	2.6	10
21	Integrative analysis of multi-platform reverse-phase protein array data for the pharmacodynamic assessment of response to targeted therapies. <i>Scientific Reports</i> , 2020, 10, 21985.	3.3	9
22	Trichoplein binds <scp>PCM</scp> 1 and controls endothelial cell function by regulating autophagy. <i>EMBO Reports</i> , 2020, 21, e48192.	4.5	17
23	An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis. <i>Nature Communications</i> , 2019, 10, 2901.	12.8	24
24	N-cadherin stabilises neural identity by dampening anti-neural signals. <i>Development (Cambridge)</i> , 2019, 146, .	2.5	17
25	Mammary Tumor Cells with High Metastatic Potential Are Hypersensitive to Macrophage-Derived HGF. <i>Cancer Immunology Research</i> , 2019, 7, 2052-2064.	3.4	15
26	A computationally designed binding mode flip leads to a novel class of potent tri-vector cyclophilin inhibitors. <i>Chemical Science</i> , 2019, 10, 542-547.	7.4	17
27	Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8⁺ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells. <i>Journal of Visualized Experiments</i> , 2019, , .	0.3	7
28	The oncogene Gankyrin is expressed in testicular cancer and contributes to cisplatin sensitivity in embryonal carcinoma cells. <i>BMC Cancer</i> , 2019, 19, 1124.	2.6	9
29	Reversal of proliferation deficits caused by chromosome 16p13.11 microduplication through targeting NFÎ³B signaling: an integrated study of patient-derived neuronal precursor cells, cerebral organoids and in vivo brain imaging. <i>Molecular Psychiatry</i> , 2019, 24, 294-311.	7.9	36
30	Evaluation of Machine Learning Classifiers to Predict Compound Mechanism of Action When Transferred across Distinct Cell Lines. <i>SLAS Discovery</i> , 2019, 24, 224-233.	2.7	13
31	Drug Screening Platforms and RPPA. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1188, 203-226.	1.6	4
32	Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach. <i>Scientific Reports</i> , 2018, 8, 5527.	3.3	15
33	High-Precision Photothermal Ablation Using Biocompatible Palladium Nanoparticles and Laser Scanning Microscopy. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 3341-3348.	8.0	28
34	Machine Learning Enables Live Label-Free Phenotypic Screening in Three Dimensions. <i>Assay and Drug Development Technologies</i> , 2018, 16, 51-63.	1.2	8
35	Pharmaco-genomic investigations of organo-iridium anticancer complexes reveal novel mechanism of action. <i>Metallomics</i> , 2018, 10, 93-107.	2.4	39
36	ALDH1 Bio-activates Nifuroxazide to Eradicate ALDHHigh Melanoma-Initiating Cells. <i>Cell Chemical Biology</i> , 2018, 25, 1456-1469.e6.	5.2	43

#	ARTICLE	IF	CITATIONS
37	Concerns, challenges and promises of high-content analysis of 3D cellular models. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 606-606.	46.4	64
38	High-Dimensional Profiling: The Theta Comparative Cell Scoring Method. <i>Methods in Molecular Biology</i> , 2018, 1787, 171-181.	0.9	3
39	Global histone modification fingerprinting in human cells using epigenetic reverse phase protein array. <i>Cell Death Discovery</i> , 2017, 3, 16077.	4.7	12
40	Reverse Phase Protein Arrays and Drug Discovery. <i>Methods in Molecular Biology</i> , 2017, 1647, 153-169.	0.9	12
41	TRPA1-FCGR2 binding event is a regulatory oncogenic driver modulated by miRNA-142-3p. <i>Nature Communications</i> , 2017, 8, 947.	12.8	56
42	Empirical drug discovery: a view from the proteome. <i>Drug Discovery Today: Technologies</i> , 2017, 23, 1-5.	4.0	6
43	Reverse Phase Protein Arrays elucidate mechanisms-of-action and phenotypic response in 2D and 3D models. <i>Drug Discovery Today: Technologies</i> , 2017, 23, 7-16.	4.0	11
44	Accelerating glioblastoma drug discovery: Convergence of patient-derived models, genome editing and phenotypic screening. <i>Molecular and Cellular Neurosciences</i> , 2017, 80, 198-207.	2.2	20
45	Monocytes Differentiate to Immune Suppressive Precursors of Metastasis-Associated Macrophages in Mouse Models of Metastatic Breast Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 2004.	4.8	122
46	Naturally Inspired Peptide Leads: Alanine Scanning Reveals an Actin-Targeting Thiazole Analogue of Bisbromoamide. <i>ChemBioChem</i> , 2016, 17, 1621-1627.	2.6	8
47	Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4697-4710.	6.4	52
48	Screening out irrelevant cell-based models of disease. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 751-769.	46.4	402
49	Development of the Theta Comparative Cell Scoring Method to Quantify Diverse Phenotypic Responses Between Distinct Cell Types. <i>Assay and Drug Development Technologies</i> , 2016, 14, 395-406.	1.2	17
50	Next-generation phenotypic screening. <i>Future Medicinal Chemistry</i> , 2016, 8, 1331-1347.	2.3	39
51	Bistability in the Rac1, PAK, and RhoA Signaling Network Drives Actin Cytoskeleton Dynamics and Cell Motility Switches. <i>Cell Systems</i> , 2016, 2, 38-48.	6.2	159
52	eCF309: a potent, selective and cell-permeable mTOR inhibitor. <i>MedChemComm</i> , 2016, 7, 471-477.	3.4	18
53	Palladium-Mediated Dealkylation of N-Propargyl-Floxuridine as a Bioorthogonal Oxygen-Independent Prodrug Strategy. <i>Scientific Reports</i> , 2015, 5, 9329.	3.3	61
54	ADF and Cofilin1 Control Actin Stress Fibers, Nuclear Integrity, and Cell Survival. <i>Cell Reports</i> , 2015, 13, 1949-1964.	6.4	70

#	ARTICLE	IF	CITATIONS
55	Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma. <i>Cancer Cell</i> , 2015, 27, 85-96.	16.8	188
56	Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E3800-5.	7.1	71
57	FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis. <i>Journal of Experimental Medicine</i> , 2015, 212, 1433-1448.	8.5	186
58	Calpain. , 2015, , 729-732.		0
59	FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis. <i>Journal of Cell Biology</i> , 2015, 210, 2104OIA168.	5.2	1
60	Quantitative phenotypic and pathway profiling guides rational drug combination strategies. <i>Frontiers in Pharmacology</i> , 2014, 5, 118.	3.5	22
61	Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational, and Basic Research: A Workshop Report. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 1625-1643.	3.8	152
62	Developments in preclinical cancer imaging: innovating the discovery of therapeutics. <i>Nature Reviews Cancer</i> , 2014, 14, 314-328.	28.4	134
63	Development and Bioorthogonal Activation of Palladium-Labile Prodrugs of Gemcitabine. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 5395-5404.	6.4	169
64	Extracellular palladium-catalysed dealkylation of 5-fluoro-1-propargyl-uracil as a bioorthogonally activated prodrug approach. <i>Nature Communications</i> , 2014, 5, 3277.	12.8	264
65	N-alkynyl derivatives of 5-fluorouracil: susceptibility to palladium-mediated dealkylation and toxicity in cancer cell culture. <i>Frontiers in Chemistry</i> , 2014, 2, 56.	3.6	22
66	High-Content Analysis to Leverage a Robust Phenotypic Profiling Approach to Vascular Modulation. <i>Journal of Biomolecular Screening</i> , 2013, 18, 1246-1259.	2.6	13
67	Comparison of Methods for Image-Based Profiling of Cellular Morphological Responses to Small-Molecule Treatment. <i>Journal of Biomolecular Screening</i> , 2013, 18, 1321-1329.	2.6	166
68	Intravital FLIM-FRET Imaging Reveals Dasatinib-Induced Spatial Control of Src in Pancreatic Cancer. <i>Cancer Research</i> , 2013, 73, 4674-4686.	0.9	111
69	Inhibition of NF- κ B Signaling Ablates the Invasive Phenotype of Glioblastoma. <i>Molecular Cancer Research</i> , 2013, 11, 1611-1623.	3.4	66
70	Advanced intravital subcellular imaging reveals vital three-dimensional signalling events driving cancer cell behaviour and drug responses in live tissue. <i>FEBS Journal</i> , 2013, 280, 5177-5197.	4.7	10
71	Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells. <i>EMBO Molecular Medicine</i> , 2013, 5, 1335-1350.	6.9	80
72	Dasatinib inhibits mammary tumour development in a genetically engineered mouse model. <i>Journal of Pathology</i> , 2013, 230, 430-440.	4.5	14

#	ARTICLE	IF	CITATIONS
73	Advancing cancer drug discovery towards more agile development of targeted combination therapies. <i>Future Medicinal Chemistry</i> , 2012, 4, 87-105.	2.3	19
74	Combining imaging and pathway profiling: an alternative approach to cancer drug discovery. <i>Drug Discovery Today</i> , 2012, 17, 203-214.	6.4	18
75	FLIM-FRET imaging in vivo reveals 3D-environment spatially regulates RhoGTPase activity during cancer cell invasion. <i>Small GTPases</i> , 2011, 2, 239-244.	1.6	25
76	Modelling distinct modes of tumour invasion and metastasis. <i>Drug Discovery Today: Disease Models</i> , 2011, 8, 103-112.	1.2	5
77	Live Cell in Vitro and in Vivo Imaging Applications: Accelerating Drug Discovery. <i>Pharmaceutics</i> , 2011, 3, 141-170.	4.5	60
78	The calpain system and cancer. <i>Nature Reviews Cancer</i> , 2011, 11, 364-374.	28.4	333
79	Spatial Regulation of RhoA Activity during Pancreatic Cancer Cell Invasion Driven by Mutant p53. <i>Cancer Research</i> , 2011, 71, 747-757.	0.9	127
80	High-Content Phenotypic Profiling of Drug Response Signatures across Distinct Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1913-1926.	4.1	147
81	Real-time Study of E-Cadherin and Membrane Dynamics in Living Animals: Implications for Disease Modeling and Drug Development. <i>Cancer Research</i> , 2009, 69, 2714-2719.	0.9	64
82	Profiling distinct mechanisms of tumour invasion for drug discovery: imaging adhesion, signalling and matrix turnover. <i>Clinical and Experimental Metastasis</i> , 2009, 26, 381-397.	3.3	29
83	Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. <i>Molecular Oncology</i> , 2009, 3, 248-261.	4.6	190
84	Assaying Calpain Activity. <i>Methods in Molecular Biology</i> , 2007, 370, 109-119.	0.9	4
85	Inhibition of calpain stabilises podosomes and impairs dendritic cell motility. <i>Journal of Cell Science</i> , 2006, 119, 2375-2385.	2.0	115
86	AP-1 Differentially Expressed Proteins Krp1 and Fibronectin Cooperatively Enhance Rho-ROCK-Independent Mesenchymal Invasion by Altering the Function, Localization, and Activity of Nondifferentially Expressed Proteins. <i>Molecular and Cellular Biology</i> , 2006, 26, 1480-1495.	2.3	37
87	The role of focal-adhesion kinase in cancer – a new therapeutic opportunity. <i>Nature Reviews Cancer</i> , 2005, 5, 505-515.	28.4	932
88	Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. <i>Trends in Cell Biology</i> , 2004, 14, 241-249.	7.9	330
89	Role of Discoidin Domain Receptors 1 and 2 in Human Smooth Muscle Cell-Mediated Collagen Remodeling. <i>American Journal of Pathology</i> , 2004, 164, 1575-1585.	3.8	158
90	A Novel Role for FAK as a Protease-Targeting Adaptor Protein. <i>Current Biology</i> , 2003, 13, 1442-1450.	3.9	177

#	ARTICLE	IF	CITATIONS
91	Calpain: a role in cell transformation and migration. <i>International Journal of Biochemistry and Cell Biology</i> , 2002, 34, 1539-1543.	2.8	130
92	v-SRC'S hold over actin and cell adhesions. <i>Nature Reviews Molecular Cell Biology</i> , 2002, 3, 233-245.	37.0	286
93	The mechanism of cell cycle regulation by v-Src. <i>Oncogene</i> , 2001, 20, 5941-5950.	5.9	48
94	Cleavage of Focal Adhesion Kinase by Different Proteases during Src-regulated Transformation and Apoptosis. <i>Journal of Biological Chemistry</i> , 2001, 276, 4270-4275.	3.4	125
95	The Extracellular Matrix Dynamically Regulates Smooth Muscle Cell Responsiveness to PDGF ^a . <i>Annals of the New York Academy of Sciences</i> , 2000, 902, 39-52.	3.8	81
96	Degraded Collagen Fragments Promote Rapid Disassembly of Smooth Muscle Focal Adhesions That Correlates with Cleavage of Pp125FAK, Paxillin, and Talin. <i>Journal of Cell Biology</i> , 1999, 147, 619-630.	5.2	229